Characteristics and outcome of pediatric patients enrolled in phase I oncology trials

Oncologist

Volumn 13, Issue 6, 2008, Pages 679-689

  Kim, Aerang ^a   Fox, Elizabeth ^a   Warren, Katherine ^a   Blaney, Susan M ^b   Berg, Stacey L ^b   Adamson, Peter C ^c   Libucha, Madeleine ^a   Byrley, Elena ^a   Balis, Frank M ^a   Widemann, Brigitte C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Pediatric oncology; Phase I; Survival; Toxicity

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ALITRETINOIN; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; IXABEPILONE; LEFLUNOMIDE; LOBRADIMIL; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; O 6 BENZYLGUANINE; PACLITAXEL; PHENYLACETIC ACID; RALTITREXED; RETINOIC ACID; TARIQUIDAR; TEMOZOLOMIDE; TIPIFARNIB;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SOLID TUMOR; SOMNOLENCE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PATIENT PARTICIPATION; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 46149125701     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0046     Document Type: Article

References (33)

1. Smith M, Bernstein M, Bleyer WA et al. Conduct of phase I trials in children with cancer. J Clin Oncol 1998;16:966-978.
2. Adamson PC, Blaney SM. New approaches to drug development in pediatric oncology. Cancer J 2005;11:324-330.
3. Balis FM. The Challenge of developing new therapies for childhood cancers. The Oncologist 1997;2:I-II.
4. Carlson L, Ho P, Smith M et al. Pediatric phase I drug tolerance: A review and comparison of recent adult and pediatric phase I trials. J Pediatr Hematol Oncol 1996;18:250-256.
5. Shah S, Weitman S, Langevin AM et al. Phase I therapy trials in children with cancer. J Pediatr Hematol Oncol 1998;20:431-438.
6. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: An analysis of study conduct efficiency. J Clin Oncol 2005;23:8431-8441.
7. Fox E, Widemann BC, Chen CC et al. Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine, or docetaxel. Proc Am Soc Clin Oncol 2004;23:805.
8. Lowe EA, Adamson PC, Widemann BC et al. Phase 1 trial and pharmacokinetic study of liposomal doxorubicin (TLC-D99, Myocet™) in children with refractory solid tumors. Proc Am Soc Clin Oncol 2002;21:109a.
9. Berg SL, Blaney SM, Adamson PC et al. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 1998;16:181-186.
10. Blaney SM, Seibel NL, O'Brien M et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 1997;15:1538-1543.
11. Seibel NL, Blaney SM, O'Brien M et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: A collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial Clin Cancer Res 1999;5:733-737.
12. Widemann BC, Salzer WL, Arceci RJ et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507-516.
13. Fox E, Maris JM, Widemann BC et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-4887.
14. Adamson PC, Widemann BC, Reaman GH et al. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer:Ajoint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res 2001;7:3034-3039.
15. Adamson PC, Blaney SM, Widemann BC et al. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol 2004;53:482-488.
16. Adamson PC. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. Leukemia 1994;8(suppl 3):S22-S25.
17. Warren KE, Patel MC, Aikin AA et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 2001;48:275-282.
18. Widemann B, Balis F, Reaman G et al. Pediatric phase I trial and pharmacokinetic (PK) study of ralitrexed (ZD1694, tomudex). Proc Am Soc Clin Oncol 1999;18:563a.
19. Widemann B, Fox E, Goodspeed W et al. Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors. Proc Am Soc Clin Oncol 2005;23:807s.
20. Berg SL, Blaney SM, Adamson PC et al. Phase I trial and pharmacokinetics of paclitaxel administered as a 3 hour infusion to children with refractory cancers. Proc Am Assoc Cancer Res 1998;39:322.
21. Serabe B, Adamson PC, Jakacki R et al. Phase I trial and pharmacokinetic study of sodium phenylbutyrate in children with refractory cancer. Child's Nerv Syst 1998;14:512a.
22. Serabe B, Adamson PC, Wolfe R et al. Phase I trial and pharmacokinetic study of phenylacetate given as a 28-day continuous infusion in children. Proc Am Assoc Cancer Res 1997;38:224.
23. Fox E, Maris JM, Widemann BC et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:1111-1115.
24. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
26. Kurmasheva R, Morton C, Houghton PJ. Developing new agents for the treatment of childhood cancer. Curr Opin Investig Drugs 2005;6:1215-1227.
27. Genre D, Viens P, Von Hoff DD et al. Patients who are receiving concomitant medications should not systematically be excluded from phase I studies. Anticancer Drugs 1999;10:1-7.
28. Fox E, Widemann BC, Maris JM et al. The pharmacokinetics and pharmacodynamics of ABT-751 in children with recurrent neuroblastoma and other solid tumors. Proc Am Soc Clin Oncol 2007;25:540s.
29. Young NS, Maciejewski JP. Aplastic anemia. In: Hoffman R, Benz E, Shattil S et al., eds. Hematology: Basic Principles and Practice, Fourth Edition. Philadelphia: Churchill Livingstone, 2005:381-407.
30. Champlin R. Bone marrow aplasia due to radiation accidents: Pathophysiology, assessment and treatment. Baillieres Clin Haematol 1989;2:69-82.
31. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. The Oncologist 2002;7:401-409.
32. Adamson PC, Reaman G, Finklestein JZ et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol 1997;15:3330-3337.
33. Warren KE, Aikin AA, Libucha M et al. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 2005;23:7646-7653.